Brief: PharmTther Announces Post Complete Response Letter Clarification Meeting Request Granted From The FDA For Ketamine Abbreviated New Drug Application
13/11/2024 13:06
Nov 13 (Reuters) - Pharmather Holdings Ltd PHRM.CD :
* PHARMATHER ANNOUNCES POST COMPLETE RESPONSE LETTER
CLARIFICATION
MEETING REQUEST GRANTED FROM THE FDA FOR KETAMINE ABBREVIATED
NEW DRUG APPLICATION
Source text: ID:nGNX1pDpCd
Further company coverage: PHRM.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Pharmather Holdings
See all newsBrief: Pharmather Sells Ketamine ANDA, Eyes Over $25M In Milestone And Profit-Sharing Payments
Brief: Pharmather receives US FDA approval goal date for Ketamine
Brief: Pharmather Announces Update On FDA New Drug Application For Ketamine
Brief: PharmTther Announces Post Complete Response Letter Clarification Meeting Request Granted From The FDA For Ketamine Abbreviated New Drug Application
Brief: Pharmather Receives Complete Response Letter From The U.S. Food And Drug Administration For Ketamine Abbreviated New Drug Application